Virtual Library

Start Your Search

Yingzhi Lu



Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-49 - Effciency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma (ID 12346)

      12:00 - 13:30  |  Author(s): Yingzhi Lu

      • Abstract
      • Slides

      Background

      Lung squamous cell carcinoma (SqCC) is the second most common histology in non-small-cell lung carcinomas (NSCLCs). Chemotherapy of two drugs based on platinum is the standard treatment of advanced lung SqCC. However, few drugs could be selected when the disease progressed after second-line treatment. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), have shown benefit in advanced NSCLC patients. This study aimed to preliminarily assess the efficacy and safety of apatinib at a lower dosage (125-500mg/d) in patients with advanced lung squamous cell carcinoma.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Eligible patients should be definitive diagnosed SqCC, who refused chemotherapy or failed first line, second line or even later lines of chemotherapy. Key exclusion criteria included major blood vessel involvement and massive haemoptysis with the amount more than 20ml. Apatinib was given every day, and treatment was continued until disease progression or unacceptable toxic effects. Progression free survival (PFS) was assessed by Kaplan–Meier test. Tumor responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

      4c3880bb027f159e801041b1021e88e8 Result

      Total 19 patients were enrolled from June 2015 to August 2017. Among them, 12 patients suffered from distant metastases before apatinib administration; 11 patients were with ECOG 2-3. Ten patients (52.6%) received 250mg daily of apatinib, 4 received 125mg, 1 received 375mg, 2 received 425mg and 2 received 500mg daily. Two patients failed to evaluate efficacy for personal reason so that 17 patients were eligible for tumor response to apatinib evaluation. Followed up to April 2018, 14 of 19 patients were dead, and 1 year survival rate was 21.1% (4/19). The median PFS was 5.3 months (95% CI: 2.7–7.9 months). Three patients achieved partial response (PR) and the objective response rate (ORR) was 17.6% (3/17) and the total disease control rate (DCR) was 76.5% (13/17). There was no significant associations between the dose of apatinib and efficacy (p=0.648). The main adverse events were fatigue (47.4%), hypertension (36.8%), hemoptysis (26.3%), loss of appetite (26.3%), proteinuria (21.1%) and hand-foot reaction (15.8%). No grade 4 adverse event was reported. All the dead events were not drug-related by physician’s judgment.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Apatinib monotherapy at a lower dosage might be an optional choice for patients with advanced lung squamous cell carcinoma. Perspective clinical studies with large sample size are needed to validate our results.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.